

**NEW JERSEY DRUG UTILIZATION REVIEW BOARD
QUAKERBRIDGE PLAZA, BUILDING 7, Rooms 200 ABC**

October 22, 2014

<http://www.state.nj.us/humanservices/dmahs/boards/durb/>

AGENDA

- I. Call to order in accordance with New Jersey Open Public Meeting Act
- II. Roll Call
- III. Review of draft meeting summary for June 25, 2014 meeting (pages 3-8; Tab 1)
- IV. Secretary's report (page 9; Tab 2)
- V. Old Business
 - A. HMO response to DURB follow-up questions regarding protocols (pages 11-13; Tab 3)
 - B. Oxycodone utilization review (page 15; Tab 4)
 - C. Low dose quetiapine (Seroquel®) utilization review (pages 17; Tab 5)
- VI. New Business
 - A. Protocols review (pages 19-24; Tab 6)
 1. Topical lidocaine (Lidoderm®)
 2. Linezolid (Zyvox®)
 - B. DURB Annual Report for SFY 2014 – distributed to board members for comments
- VII. Informational Highlights/Reports
 1. Molina/NJ HMO 2nd Quarter 2014 Prior Authorization Report (pages 25-26; Tab 7)
 2. Summary of DURB Action Items (pages 27-28; Tab 8)
 3. DHS and DHSS Programs Top Drugs Report (pages 29-40; Tab 9)
 4. Medication information: (pages 41-51; Tab 10)
 - (a) Study: Emergency Hospitalizations for Unsupervised Prescription Medication Ingestions by Young Children
 - (b) Guidance for Pharmacists Dispensing Naloxone – New Jersey office of AG
 - (c) Analysis of “Real World” Sovaldi® (sofosbuvir) Use and Discontinuation Rates
 - (d) DEA Classifies Tramadol a Controlled Substance
 - (e) Study: Psych drug ER trips approach 90,000 a year